Pulmonary Autotaxin Expression Contributes to the Pathogenesis of Pulmonary Fibrosis

Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis

(2012) Ioanna Nikitopoulou et al.   JOURNAL OF EXPERIMENTAL MEDICINE

An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

(2011) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

The Lysophosphatidic Acid Receptor LPA1Promotes Epithelial Cell Apoptosis after Lung Injury

(2011) Manuela Funke et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Blockade of lysophosphatidic acid receptors LPAR1/3 ameliorates lung fibrosis induced by irradiation

(2011) Lu Gan et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways

(2011) Jing Zhao et al.   BIOCHEMICAL JOURNAL

Aromatic phosphonates inhibit the lysophospholipase D activity of autotaxin

(2011) Guowei Jiang et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Modeling pulmonary fibrosis with bleomycin

(2011) Marios A. Mouratis et al.   CURRENT OPINION IN PULMONARY MEDICINE

Integrating mechanisms of pulmonary fibrosis

(2011) Thomas A. Wynn   JOURNAL OF EXPERIMENTAL MEDICINE

Pirfenidone for idiopathic pulmonary fibrosis

(2011) Demosthenes Bouros   LANCET

Insights into autotaxin: how to produce and present a lipid mediator

(2011) Wouter H. Moolenaar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model

(2010) JS Swaney et al.   BRITISH JOURNAL OF PHARMACOLOGY

ATX expression and LPA signalling are vital for the development of the nervous system

(2010) Stella Fotopoulou et al.   DEVELOPMENTAL BIOLOGY

Autotaxin expression and its connection with the TNF-alpha-NF-κB axis in human hepatocellular carcinoma

(2010) Jian-Min Wu et al.   Molecular Cancer

Strategies for treating idiopathic pulmonary fibrosis

(2010) R. M. du Bois   NATURE REVIEWS DRUG DISCOVERY

International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature

(2010) J. Chun et al.   PHARMACOLOGICAL REVIEWS

The pathogenesis of idiopathic pulmonary fibrosis

(2010) William R. Coward et al.   Therapeutic Advances in Respiratory Disease

Dual Activity Lysophosphatidic Acid Receptor Pan-Antagonist/Autotaxin Inhibitor Reduces Breast Cancer Cell Migration In vitro and Causes Tumor Regression In vivo

(2009) Honglu Zhang et al.   CANCER RESEARCH

Autotaxin/Lysopholipase D and Lysophosphatidic Acid Regulate Murine Hemostasis and Thrombosis

(2009) Zehra Pamuklar et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Prostaglandin F2α receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-β

(2009) Toru Oga et al.   NATURE MEDICINE

G2A and LPC: Regulatory functions in immunity

(2009) Janusz H. Kabarowski   PROSTAGLANDINS & OTHER LIPID MEDIATORS

Lysophosphatidic acid (LPA) receptors: Signaling properties and disease relevance

(2009) Mu-En Lin et al.   PROSTAGLANDINS & OTHER LIPID MEDIATORS

Gelsolin expression is necessary for the development of modelled pulmonary inflammation and fibrosis

(2009) N Oikonomou et al.   THORAX

Lipopolysaccharide induces autotaxin expression in human monocytic THP-1 cells

(2008) Song Li et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Two pathways for lysophosphatidic acid production

(2008) J AOKI   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Lysophosphatidic acid signaling in airway epithelium: Role in airway inflammation and remodeling

(2008) Yutong Zhao et al.   CELLULAR SIGNALLING

Murine and Human Autotaxin α, β, and γ Isoforms

(2008) Adeline Giganti et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

S32826, A Nanomolar Inhibitor of Autotaxin: Discovery, Synthesis and Applications as a Pharmacological Tool

(2008) G. Ferry et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS